Skip to content

Cell therapy in infertile women with Diminished Ovarian Reserve

Investigating the effectiveness of autologous Platelet-Rich Plasma and Condition Medium of mesenchymal stem cells derived from the umbilical cord on the serum level of Anti Mullerian Hormone in infertile women with Diminished Ovarian Reserve

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231230060569N2
Enrollment
44
Registered
2024-12-30
Start date
2025-01-20
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished Ovarian Reserve(DOR). Ovarian dysfunction, unspecified

Interventions

Intervention 1: Intervention group: Injection of 1 ml of autologous PRP in 1 step into the ovaries of DOR patients under mild anesthesia with ultrasound guidance. Intervention 2: Intervention group:

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Women between 20 and 45 years old Having poor or diminished ovarian reserve and having one of the criteria for poor ovarian response, which are: total number of Antral Follicles Count in both ovaries 7 or less on vaginal ultrasound, AMH less than 1.1 ng/ml, history of IVF with 3 or fewer eggs Reading and signing the informed consent form

Exclusion criteria

Exclusion criteria: Pregnancy History or current IgA deficiency History of surgery leading to pelvic adhesions Taking anticoagulant medications Mental illness with dependence on drug use Chronic malignancies or chronic pelvic pain Infertility due to severe male factor Drug addiction Endometriosis and abnormal uterine shape observed in hysterosalpingogram Failure to sign the informed consent form

Design outcomes

Primary

MeasureTime frame
Anti Mullerian Hormone. Timepoint: before injection and 2, 6 and 14 weeks after injection. Method of measurement: ELISA KIT.;Antral Follicle Count(AFC). Timepoint: before injection and 2, 6 and 14 weeks after injection. Method of measurement: Vaginal ultrasound.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManizheh Habibpour

Mazandaran University of Medical Sciences

manizheh.habibpour@yahoo.com+98 11 3334 2905

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026